Pharmaceuticals

Systemic Amyloidosis Therapeutics Market Expected to Approach $8.87 Billion by 2030

April 8, 2026April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Systemic Amyloidosis Therapeutic Market During The Forecast Period 2026–2030?

The size of the systemic amyloidosis therapeutic market has demonstrated robust growth over recent years. The market is forecast to expand, moving from $5.67 billion in 2025 to $6.2 billion in 2026, at a compound annual growth rate (CAGR) of 9.2%. Key drivers behind this historical growth include the prior underdiagnosis of amyloidosis, the use of chemotherapy regimens, an expansion in hematology treatment centers, heightened rare disease awareness, and the initial integration of proteasome inhibitors.

The systemic amyloidosis therapeutic market is anticipated to experience substantial expansion in the coming years. It is projected to reach $8.88 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. This growth during the forecast period can be attributed to rising rare disease diagnosis rates, the expansion of targeted biologic drugs, an increase in gene silencing therapy approvals, the development of specialized clinic networks, and stronger orphan drug incentives. Key trends expected in the forecast period include targeted amyloid protein stabilizer drugs, gene silencing amyloidosis therapies, monoclonal antibody-based treatments, combination regimen treatment protocols, and organ-specific supportive drug strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33337&type=smp

Which Market Drivers Are Supporting The Expansion Of The Systemic Amyloidosis Therapeutic Market?

The expanding acceptance of personalized medicine methodologies is anticipated to fuel the advancement of the systemic amyloidosis therapeutic market moving forward. Personalized medicine refers to a medical methodology that customizes treatment and prevention plans based on an individual’s distinct genetic makeup, biomarkers, and specific disease characteristics. The escalating demand for personalized medicine stems from advancements in genomic and biomarker technologies, which empower clinicians to precisely pinpoint disease mechanisms and customize treatments, thereby enhancing effectiveness and mitigating adverse reactions for individual patients. The integration of personalized medicine elevates the demand for systemic amyloidosis therapeutics because patients afflicted with systemic amyloidosis present with diverse amyloid subtypes (e.g., AL, ATTR) and genetic variations. Consequently, successful treatment necessitates therapies precisely engineered to address the patient’s unique disease profile, guaranteeing maximum therapeutic benefit and minimal unwanted effects. For example, in April 2025, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit advocacy and educational organization, indicated that in 2023, the FDA gave its approval to 16 novel personalized treatments for patients with rare diseases, marking an increase from six approvals in 2022. Therefore, the wider implementation of personalized medicine approaches is acting as a catalyst for the growth of the systemic amyloidosis therapeutic market.

What Market Segments Are Evaluated Within The Systemic Amyloidosis Therapeutic Market?

The systemic amyloidosis therapeutic market covered in this report is segmented –

1) By Product Type: Small Molecule Drugs; Biologic Therapies; Monoclonal Antibodies; Chemotherapy Based Regimens; Targeted Therapies; Supportive Treatments

2) By Formulation: Tablets; Capsules; Injection

3) By Route of Administration: Oral; Intravenous; Subcutaneous

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

5) By End User: Hospitals; Specialty Clinics; Specialty Pharmacies; Research and Academic Institutes; Other End Users

Subsegments:

1) By Small Molecule Drugs: Proteasome Inhibitors; Stabilizers of Transthyretin Protein; Amyloid Fibril Disruptors; Immunomodulatory Small Molecules

2) By Biologic Therapies: Recombinant Protein Therapies; Gene Silencing Biologic Agents; Plasma Derived Biologic Products

3) By Monoclonal Antibodies: Anti Amyloid Fibril Antibodies; Anti Light Chain Antibodies; Targeted Clearance Antibodies

4) By Chemotherapy Based Regimens: Alkylating Agent Based Regimens; Proteasome Inhibitor Based Chemotherapy; Combination Chemotherapy Protocols

5) By Targeted Therapies: Targeted Light Chain Suppression Therapies; Targeted Transthyretin Reduction Therapies; Organ Specific Targeted Treatments

6) By Supportive Treatments: Cardiac Supportive Therapies; Renal Supportive Therapies; Neurological Symptom Management Therapies; Nutritional and Palliative Care Therapies

What Industry Trends Are Redefining The Systemic Amyloidosis Therapeutic Market?

Leading companies in the systemic amyloidosis therapeutic market are concentrating on developing advanced, targeted treatment methods, including RNA interference-based therapies. These strategies aim to address the fundamental genetic origins of protein misfolding conditions, reduce disease progression, and enhance patients’ long-term health results. RNA interference-based therapies operate by precisely inhibiting specific disease-causing genes, thereby diminishing the creation of detrimental proteins responsible for widespread organ damage. As an illustration, in March 2025, Alnylam Pharmaceuticals, a US-based biotechnology company, introduced AMVUTTRA. AMVUTTRA provides a specific, disease-altering therapy for adults suffering from transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Developed by Alnylam Pharmaceuticals, it is notable as the initial RNAi therapeutic proven to lessen cardiovascular mortality, hospital admissions, and urgent visits for heart failure among this patient group. AMVUTTRA functions by swiftly suppressing transthyretin production at its origin, confronting the underlying reason for amyloid accumulation. It has shown consistent advantages across various aspects, including cardiovascular outcomes, functional capabilities, and overall quality of life.

Who Are The Prominent Organizations Shaping The Systemic Amyloidosis Therapeutic Market?

Major companies operating in the systemic amyloidosis therapeutic market are Johnson & Johnson Services Inc., Sanofi SA, Novartis Plc, AstraZeneca Plc, GSK Plc, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals, Arcturus Therapeutics Inc, Prothena Biosciences, Fortress Biotech Inc., Intellia Therapeutics Inc., Zentalis Pharmaceuticals Inc., BridgeBio Pharma Inc., Neurimmune AG, HaemaLogix Pty Ltd., Attralus Inc., and Oncopeptides AB.

Read the full systemic amyloidosis therapeutic market report here:

https://www.thebusinessresearchcompany.com/report/systemic-amyloidosis-therapeutic-market-report

Which Region Is Projected To Lead The Systemic Amyloidosis Therapeutic Market During The Forecast Period?

North America was the largest region in the systemic amyloidosis therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic amyloidosis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Systemic Amyloidosis Therapeutic Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33337&type=smp

Browse Through More Reports Similar to the Global Systemic Amyloidosis Therapeutic Market 2026, By The Business Research Company

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Atrophic Glossitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795